56+ min ago   (196+ words) Ann Cleves on why the future of small-molecule drug discovery lies beyond the rule of five What was your biggest professional highlight of the past 12 months? Have small molecules been overshadowed by newer modalities – and where do they still hold…...

23+ hour, 47+ min ago   (1007+ words) Why early process development, analytical planning, and tech transfer can shape the future of cell and gene therapy manufacturing Cell and gene therapy processes built for early trials may not always be ready for commercial supply, where consistency, capacity, cost,…...

4+ day, 2+ hour ago   (295+ words) Ali Pashazadeh argues that management failures sink too many clinical programs – and explains why commercial discipline must start much earlier What was your biggest professional highlight of the past 12 months? Where is the biopharma industry making real progress that isn’t…...

5+ day, 1+ hour ago   (997+ words) Samsung Biologics’ Sojeong Lee discusses why biologics developers are paying closer attention to glycosylation earlier in development. As biologics pipelines expand beyond conventional monoclonal antibodies, developers are facing new questions about how best to manage product quality, consistency, and performance....

6+ day, 1+ hour ago   (1438+ words) In part two of our conversation, Lingshi Tan explores how China’s integrated biopharma ecosystem is reshaping assumptions about speed, cost, innovation, and cross-border clinical development China’s rise in biopharma is often framed as a competitive challenge to the West. For…...

1+ week, 3+ hour ago   (375+ words) Ten industry leaders from the 2026 Power List identify the scientific, clinical, regulatory, and financial barriers holding drug development back The biggest bottleneck slowing progress in drug development is the competition for, and successful recruitment of, patients for participation in clinical…...

1+ week, 3+ day ago   (251+ words) Nominations are now open for The Medicine Maker 2026 Innovation Awards, celebrating the latest technologies for drug development and manufacturing Nominations for the Innovation Awards will remain open until September 27, 2026. The nomination form is available below. To be eligible for inclusion,…...

2+ week, 18+ hour ago   (147+ words) AI can help formulation teams better predict performance and allocate resources, but proprietary data protections remain a critical bottleneck AI’s expanding role in solubility and bioavailability prediction In a CDMO context, these advantages are constrained by confidentiality requirements. Client owned…...

2+ week, 3+ day ago   (1238+ words) For Biopharma Vital Signs, we asked industry leaders for their views on the state of biotech and biopharma today – including the trends shaping development, the pressure points slowing progress, and the practical challenges companies are navigating as programs advance. Explore…...

2+ week, 4+ day ago   (625+ words) Mission Bio’s Mike Molnar explains how single-cell multiomics could improve vector copy number analysis, product characterization, and safety assessment in CAR T development CAR T therapies are complex, heterogeneous cell products, but many standard analytical methods still report only population-level…...